




Searching News Database: GW Pharmaceuticals
HSMN NewsFeed - 11 Apr 2016
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
HSMN NewsFeed - 11 May 2015
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
HSMN NewsFeed - 31 Mar 2015
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
HSMN NewsFeed - 28 Apr 2014
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
HSMN NewsFeed - 27 Nov 2013
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
HSMN NewsFeed - 22 Jul 2013
GW Pharmaceuticals Files New Regulatory Application to Expand Sativex(R) Approval to France
GW Pharmaceuticals Files New Regulatory Application to Expand Sativex(R) Approval to France
Additional items found! 1

Members Archive contains
1 additional stories matching:
GW Pharmaceuticals
(Password required)
GW Pharmaceuticals
(Password required)